NCT07746947Recruiting
PROMISE Registry: PROspective Study on Management of Ischemic Stroke Secondary to mEvo Registry
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
Investigators are conducting a real world, observational, prospective, multicenter study to better understand treatment for patients with MeVo and distal vessel occlusions in the U.S post publication of recent MeVO trials.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 652 (estimated)
- First submitted
- 17 Jul 2026
- Start date
- 11 Jul 2026
- Primary completion date
- 11 Jul 2029
- Lead sponsor
- Indiana University
- Diseases
- Stroke
- NCT number
- NCT07746947
What you commit to
- Study type: Observational
- Planned participants: 652
- From 11 Jul 2026 to the primary completion date, 11 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intracranial tumors other than small meningioma that does not require surgery for one year post randomization.
- Life expectancy is less than one year prior to stroke onset14. Participation in another randomized clinical trial that could confound the evaluation of the study outcomes
- 15\. Any other condition (in the opinion of the site investigator) that precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was performed
Other illness
- Any intracranial hemorrhage on initial CT head non contrast
- Known pregnancy (local protocol to determine if patient is pregnant at the time of stroke)
- Known severe allergy (more than a rash) to contrast media uncontrolled by medications
- CT evidence of the following conditions:
- Midline shift or herniation
- Mass effect with effacement of the ventricles
Lab values
- Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with an International Normalized Ratio (INR) of \>3.0 or Partial Thromboplastin Time (PTT) \>3 times of normal
- Baseline platelet count \<80,000 per microliter (µl)
Age
- Age \>86
Other
- ASPECTS ≤ 5
- mRS≥3
- Acute bilateral strokes
- Contraindication to antiplatelet (aspirin, clopidogrel, ticagrelor, cangrelor) or contrast agents
Criteria the registry did not label
- Inclusion
- Acute ischemic stroke clinically eligible for immediate EVT
- Age ≥18 - 85 years of age
- Time from onset (or last-seen-well) to 24 hours
- Disabling stroke defined as follows:
- Baseline National Institutes of Health Stroke Scale (NIHSS) score \>5 B. Baseline NIHSS 3-5 with disabling deficit (e.g., hemianopia, aphasia, loss of hand function) as determined and agreed upon by two physicians in context of the patient's life
- Confirmed treatable MeVO based on neurovascular non-invasive imaging (CTA or MRA), at one or more of the following locations: M2 or M3 segment, A2 or A3 segment, P1, P2 or P3 segment
- Informed consent: Within the first 72 hours after inclusion in the study
- ASPECTS ≥5
- mRS≤2
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IU Health Neuroscience Center Coordinator of this site? Confirm its status | Indianapolis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.